Analysis of Residual solvents in pharmaceuticals

Significance of the Topic

Residual organic solvents can pose health risks in pharmaceutical products. Regulatory agencies such as ICH set limits on residual solvents to ensure drug safety and compliance. A robust analytical protocol is essential for accurate quantification of common volatile organic compounds in drug formulations.

Objectives and Study Overview

This study outlines a gas chromatography method using flame ionization detection for simultaneous analysis of 29 residual solvents in pharmaceuticals. The goal is to achieve rapid separation, reliable quantitation, and compliance with pharmacopeial standards.

Methodology

The analytical procedure employs a Shimadzu gas chromatograph equipped with an SH-I-624Sil MS capillary column. Key parameters include:

• Column dimensions: 20 m x 0.18 mm I.D., 1.00 µm film thickness
• Oven temperature program: 40 °C hold for 5 min, ramp at 50 °C/min to 260 °C, hold for 3 min
• Injection: 0.5 µL split injection (1:50) at 250 °C
• Carrier gas: helium at 1.35 mL/min constant flow
• Detector: FID at 250 °C, data rate 50 Hz

Used Instrumentation

The analysis was conducted on a gas chromatograph with flame ionization detector. The specific column used was the SH-I-624Sil MS (P/N 227-36075-01) providing high resolution for volatile compounds. Helium served as the carrier gas and a 5 mm split liner was installed in the injection port.

Main Results and Discussion

The method enabled baseline separation of all 29 target solvents, including alkanes, chlorinated solvents, ethers and aromatics, within a single run. The dead time at initial oven temperature was 0.74 min. Retention order corresponded to increasing boiling points and polarity. Flame ionization detection provided consistent response factors across the analyte set.

Benefits and Practical Applications

This protocol supports routine quality control laboratories in pharmaceutical manufacturing by delivering reliable quantitation of residual solvents. The fast analysis time, combined with broad analyte coverage, enhances throughput. Compliance with ICH residual solvent guidelines ensures product safety and regulatory acceptance.

Future Trends and Potential Applications

Anticipated developments include integration with mass spectrometry for improved selectivity, miniaturized systems for field deployment, and automated sample handling for high throughput screening. Novel stationary phases and green analytical techniques may further reduce analysis time and solvent consumption.

Conclusion

The described GC-FID method offers a robust, rapid and comprehensive solution for residual solvent analysis in pharmaceutical products. It fulfills regulatory requirements and can be readily implemented in QC environments.